Robert Weiss, MD
Cardiovascular Disease · Baltimore, MDNPI 1851337083
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Revance Therapeutics, Inc. at 32.2% of the total. That places this record below the midpoint for cardiovascular disease clinicians in MD, where the typical reported total is $1,418.
Across 11 payments — averaging $32.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Revance Therapeutics, Inc.$117
- Johnson & Johnson$113
- Pfizer$36
- LEO Pharma Inc.$30
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$23
- AbbVie$22
- plus $21 from 1 others
Across 15 payments — averaging $92,619 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.4M
- Medtronic$5K
What the payments were for
- Food & beverage$362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Revance Therapeutics, Inc. | 2 | $117 |
| Johnson & Johnson | 3 | $113 |
| Pfizer | 2 | $36 |
| LEO Pharma Inc. | 1 | $30 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $23 |
| AbbVie | 1 | $22 |
| Biofrontera Inc. | 1 | $21 |
How this compares
$362 in reported general payments places this provider in the 30th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.